within Pharmacolibrary.Drugs.ATC.S;

model S03AA30
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S03AA30</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This ATC code (S03AA30) refers to ophthalmologic antiinfective combinations, used topically in the treatment of eye infections, commonly in combination with corticosteroids or other agents. These are typically used to manage or prevent bacterial infections in ophthalmic conditions and are not systemically absorbed to a significant degree. Their use has been declining with the development of more targeted monotherapies and modern ophthalmic antimicrobial agents.</p><h4>Pharmacokinetics</h4><p>No published, peer-reviewed pharmacokinetic models are available for antiinfective ophthalmologic combinations with ATC S03AA30 in humans. These products are administered topically in the eye, with negligible systemic absorption and thus systemic PK parameters are not established or meaningful.</p><h4>References</h4><ol><li><p>Aggarwal, R, et al., &amp; Chauhan, MK (2020). Treatment and management strategies of onychomycosis. <i>Journal de mycologie medicale</i> 30(2) 100949–None. DOI:<a href=\"https://doi.org/10.1016/j.mycmed.2020.100949\">10.1016/j.mycmed.2020.100949</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32234349/\">https://pubmed.ncbi.nlm.nih.gov/32234349</a></p></li><li><p>Hariprasad, SM, &amp; Mieler, WF (2016). Antibiotics. <i>Developments in ophthalmology</i> 55 344–356. DOI:<a href=\"https://doi.org/10.1159/000438961\">10.1159/000438961</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26501865/\">https://pubmed.ncbi.nlm.nih.gov/26501865</a></p></li><li><p>Herbert, R, et al., &amp; Kaye, SB (2022). Potential new fluoroquinolone treatments for suspected bacterial keratitis. <i>BMJ open ophthalmology</i> 7(1) –. DOI:<a href=\"https://doi.org/10.1136/bmjophth-2022-001002\">10.1136/bmjophth-2022-001002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36161851/\">https://pubmed.ncbi.nlm.nih.gov/36161851</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S03AA30;
